If you are wondering whether Abbott Laboratories at around US$100 a share still reflects its underlying worth, you are not alone. This article is built to help you frame that question clearly.
The stock has recently pulled back, with a 2.5% decline over the last 7 days and a 9.0% decline over the last 30 days, contributing to a 19.5% decline over the last year.
Recent news coverage has focused on Abbott Laboratories as a large, diversified healthcare name that often features in discussions about medical devices and diagnostics. These ongoing conversations help frame how investors think about the company when the share price moves as it has over recent months.
Simply Wall St currently gives Abbott Laboratories a valuation score of 5 out of 6. The sections ahead will walk through the usual valuation checks before closing with a broader way to think about what that score really means for you.
A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back into today’s dollars. It focuses on the cash that could be available to shareholders rather than reported accounting earnings.
For Abbott Laboratories, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections expressed in US$. The latest twelve month free cash flow is about $7.26b. Analysts provide explicit forecasts for the next few years, and Simply Wall St then extends those out to a full ten year path.
On this basis, projected free cash flow reaches about $14.42b in 2035, with intermediate points such as $9.16b in 2026 and $10.00b in 2027. Each of these future figures is discounted back to reflect the time value of money, then combined with an estimate of cash flows beyond year ten to arrive at an intrinsic value per share.
The result of this DCF is an estimated fair value of about $132.54 per share, which compares to a current share price around $100, implying the shares trade at roughly a 24.3% discount.
For a profitable company, the P/E ratio is a useful shorthand for what investors are currently willing to pay for each dollar of earnings, which makes it a practical checkpoint alongside a DCF model.
Growth expectations and risk both affect what feels like a normal P/E range. Stronger or more predictable earnings usually support a higher multiple, while higher uncertainty often justifies a lower one. Abbott Laboratories currently trades on a P/E of 26.9x. That sits close to the Medical Equipment industry average of 26.3x, and below the peer group average of 38.0x, which suggests that the market is pricing it more conservatively than some peers.
Simply Wall St’s Fair Ratio framework goes a step further. It estimates what a P/E might be, given factors such as earnings growth, profit margins, industry, market cap and company specific risks, to arrive at a Fair Ratio of 36.2x for Abbott Laboratories. Because it ties the multiple to the company’s own fundamentals rather than just broad peer groups, it can give a more tailored anchor point. Compared to this Fair Ratio, the current 26.9x P/E sits meaningfully lower, which indicates that the shares may be undervalued on this metric.
Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to connect your view of Abbott Laboratories, including what you think future revenue, earnings and margins might look like, to a financial forecast and then to a Fair Value that you can compare with the current share price.
On Simply Wall St’s Community page, millions of investors use Narratives to attach a clear story to the numbers. Those Narratives then update automatically when fresh information such as earnings results or news headlines is added, so your Fair Value view stays in sync with the latest data rather than becoming stale.
For Abbott Laboratories, one investor might build a Narrative close to the analysts’ higher end, with a Fair Value near US$158 a share based on stronger growth and higher margins. Another might anchor near the lower end at US$113 a share with more cautious assumptions. By setting up your own Narrative between those bookends, you can see in real time whether your Fair Value sits above or below today’s price and use that gap as one input into your decision about when to buy or sell.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
